J Immunother 2010 Oct
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.
Related Questions
New answer by Medical Oncologist at Memorial Sloan Kettering Cancer Center (October 30, 2019)
This is an interesting question. PD-L1 expression confers a poor prognosis in pancreas cancer and expression was historically thought to be low, however, more recent data sugg...